Wuhan LL Science and Technology Development

Wuhan LL Science and Technology Development is a clinical-stage biotechnology company based in Wuhan, China, dedicated to the development of innovative cytokine-based immunotherapies for oncology. The company focuses on engineering next-generation interleukin-15 (IL-15) therapeutics designed to stimulate the immune system's natural ability to fight cancer. Its lead candidate, LL-101, is a recombinant human IL-15 fusion protein that mimics the natural trans-presentation of IL-15 to its receptor, enhancing the activation of T cells and Natural Killer (NK) cells. By utilizing its proprietary fusion protein platform, the company aims to improve the pharmacokinetic profile and therapeutic window of cytokines. Wuhan LL Science and Technology Development is currently advancing its pipeline through multiple clinical trials targeting various advanced solid tumors. The company represents a growing segment of the Chinese biotech sector focused on high-potency biological response modifiers.